A STUDY OF GENETIC POLYMORPHISMS OF CYTOCHROME P450 CYP 2D6 IN PATIENTS WITH CORONARY HEART DISEASE COMBINED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE TAKING A BETA-BLOCKER
Abstract
The article deals with the problems of drug therapy of patients with coronary heart disease combined with chronic obstructive pulmonary disease taking beta-blockers.
About the Authors
T. E. Morozova
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Tatyana Evgenievna Morozova, MD, prof., head of the chair of clinical pharmacology and pharmacotherapy
6 B. Pirogovskaya str., Moscow, 119992
Tel.: 8 (499) 248–75–44
O. A. Cvetkova
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
MD, prof. of the chair of clinical pharmacology and pharmacotherapy
Moscow
A. Yu. Gurova
The I.M. Sechenov First MSMU
Russian Federation
Russian Federation
PhD, assistant of of the chair of clinical pharmacology and pharmacotherapy
Moscow
References
1. Gurevich M.A. Modern approaches to the use of b-blockers // Ekonomichesky vestnik farmacii. 2003; 3(61): 63–64.
2. Metra M., Giubbini R., Nodari S. Differential effects of beta-blocers in patients with failure: a prospective, randomized, double-blind comparision of the long-term of metoprolol versus carvedilol // Circulation. 2000; 102(5): 546–551.
3. Nuttall S.L., Toescu V., Kendall M.J. Вeta-blocade after myocardial infarction // B.M.J. 2003; 320 (7234): 581–588.
4. Chen J., Radford M.J., Wang Y., Marciniak T.A., Krumholz H.M. Effectiveness of beta–blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma // J. Am. Coll. Cardiol. 2001; 37: 1950–1956.
5. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta– blockade on mortality among high–risk and low–risk patients after myocardial infarction // N. Engl. J. Med. 1998; 339: 489–497.
6. Dranseld M.T., Rowe S.M., Johnson J.E., Bailey W.C., Gerald L.B. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD // Thorax. 2008; 63: 301–305.
7. Kukes V.G., Ostroumova O.D., Mamaev V.I. et al. Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension and concomitant diabetes and obstructive pulmonary disease // Ter. arkhiv. 2003; 75(8): 43–47.
8. Gurova A.Yu., Chaplygin A.V., Svet A.V., Morozova T.E., Cvetkova O.A. Features of rational pharmacotherapy with beta-blockers in combination with coronary heart disease and chronic obstructive pulmonary disease // Lechaschy vrach. 2012; 2: 15–19.
9. Sychev D.A., Ignatjev I.V., Ramenskaya G.B., Andreev D.A., Kazakov R.E., Gasanov N.A., Isakova Zh.O., Vlaskina M.V., Bogoslovskaya S.I., Kukes V.G. Pharmacogenetic studies of biotransformation system and conveyors for personalization of pharmacotherapy in cardiology (Russian experience). Second message: CYP2D6 pharmacogenetic studies // Klinicheskaya farmakologiya i terapiya. 2007; 4: 62–66.
10. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M., Brockmöller J., Frötschl R., Köpke K., Gerloff T., Chernov J.N., Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population // Eur. J. Clin. Pharmacol. 2003; 59(4): 303–312.
11. Wuttke H., Rau T., Heide R., Bergmann K., Bohm M., Weil J., Werner D., Eschenhagen T. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprololassociated adverse effects // Clin. Pharmacol. Ther. 2002; 72(4): 429–347.
12. Wuttke H., Rau T., Heide R., Bergmann K., Bohm M., Weil J., Werner D., Eschenhagen T. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprololassociated adverse effects // Clin. Pharmacol. Ther. 2002; 72(4): 429–347.
13. Lefebvre J., Poirier L., Poirier P., Turgeon J., Lacourciere Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension // British journal of clinical pharmacology. 2007; 63(5): 575–582.
14. Lindamood C., Ortiz S., Shaw A., Rackley R., Gorski J.C. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies // Journal of clinical pharmacology. 2011. 51(4): 575–585.
15. Gurova A.Yu., Durnetsova O.S., Morozova T.E., Cvetkova O.A. Possibility of beta-blockers in patients with comorbidity // Kardiosomatika. 2011; 4: 48–53.
Review
Views:
237
Email this article 